Sunday, April 17, 2022

Johnson & Johnson vaccine partner Emergent still lacks FDA’s manufacturing green light


The U.S. manufacturing partner turning out drug substance for Johnson & Johnson’s single-dose COVID-19 vaccine is still waiting on an FDA green light, potentially putting a squeeze on J&J’s supply pipeline.

The FDA is weighing an emergency nod for Emergent BioSolutions, tapped in July 2020 to provide large scale drug substance manufacturing for J&J’s shot, Politico reported, citing two people familiar with the company’s emergency use authorization process.

The regulator could clear Emergent “very soon,” one source said.

While Emergent has been shipping millions of doses to J&J’s U.S. fill-finish partner Catalent, which itself snared authorization last week, those shots can’t be used until Emergent earns its emergency nod. In the meantime, J&J has been flying in drug substance from the Netherlands, one source told Politico.

Emergent didn’t immediately respond to Fierce Pharma’s request for comment.

RELATED: Johnson & Johnson to sell another 100M coronavirus vaccine doses to U.S., taking America’s supply to 800M doses: reports

The issue stems from the fact that J&J didn’t include its manufacturing partners in its original emergency use application, Politico said. In recent weeks, Biden administration officials have raised flags about whether the company can meet its delivery goal.

But Johnson & Johnson says it’s on track to provide a promised 20 million doses by the end of the month and 100 million by June, a company spokesperson said via email.

“To meet our global commitments, we have established a global vaccine supply network where multiple manufacturing sites are involved in the production of the vaccine across different facilities, sometimes in different countries and continents, before the vaccine can be distributed globally once authorized for use by health authorities,” the spokesperson said.

The company expects to deliver more than 1 billion COVID-19 vaccine doses this year and is in good shape to meet its 2021 supply pledges, he added. As of Monday, around 5 million J&J vaccines had been deployed in the U.S., according to the Centers for Disease Control and Prevention.

The news of Emergent’s impending emergency nod follows last week’s authorization of Catalent’s Bloomington, Indiana plant, where the CDMO in April agreed to reserve space for fill-finish work. The move could allow Catalent to release millions of vials that have already been packaged and inspected, Bloomberg reported last week, citing anonymous sources.

RELATED: The top 20 pharma companies by 2020 revenue

Catalent will soon play an upsized role in J&J’s European manufacturing operation, too, thanks to a second high-speed vial-filling line the CDMO is adding at its fill-finish plant in Anagni, Italy. The upgrade, pegged for completion in the fourth quarter, should double capacity at the facility, Catalent said.

J&J aims to deliver 200 million doses to the European Union this year.

As J&J’s shot starts rolling out around the world, the company continues to strike supply deals. On Monday, the drugmaker said it would provide the African Union with up to 400 million doses through 2022. Deliveries from an initial 220 million-dose tranche are expected to begin in the third quarter, with the remaining shots to roll out through next year.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...